A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)

An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)

NCT01689025 ·Status: TERMINATED ·Phase: PHASE1

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy Participants

NCT05984251 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)

NCT03724916 ·Status: COMPLETED ·Phase: PHASE1

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

NCT05843643 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Pharmacodynamics Assessment Study After Single Subcutaneous Dose Of SAR113244 Versus Placebo In Lupus Male And Female Patients

NCT02331810 ·Status: WITHDRAWN ·Phase: PHASE1

Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches

NCT02270957 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus Erythematosus

NCT00482989 ·Status: COMPLETED ·Phase: PHASE1

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)

NCT06977724 ·Status: RECRUITING ·Phase: PHASE1

Subgrouping SLE - a New Approach to Understand the Pathogenesis and Improve Treatment

NCT07102030 ·Status: RECRUITING

Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE

NCT01702038 ·Status: WITHDRAWN ·Phase: PHASE2

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

NCT06897930 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease

NCT00035308 ·Status: COMPLETED ·Phase: PHASE3

A Study of LY2127399 in Participants With Systemic Lupus Erythematosus

NCT01196091 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus

NCT00137969 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).

NCT06335979 ·Status: RECRUITING ·Phase: PHASE1

Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

NCT04186871 ·Status: COMPLETED ·Phase: PHASE2

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

NCT06916806 ·Status: RECRUITING ·Phase: PHASE1

Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)

NCT00113971 ·Status: TERMINATED ·Phase: PHASE2

A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

NCT03978520 ·Status: COMPLETED ·Phase: PHASE2

Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)

NCT00299819 ·Status: COMPLETED ·Phase: PHASE1

Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus

NCT06333483 ·Status: RECRUITING ·Phase: PHASE1

An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184

NCT01777256 ·Status: TERMINATED ·Phase: PHASE2

Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus

NCT02554019 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus

NCT06429800 ·Status: WITHDRAWN ·Phase: PHASE1

BI 705564 in Patients With Systemic Lupus Erythematosus (SLE)

NCT03771885 ·Status: WITHDRAWN ·Phase: PHASE1